An epigenetic biomarker combination of PCDH17 and POU4F2 detects bladder cancer accurately by methylation analyses of urine sediment DNA in Han Chinese

Oncotarget

Volumn 7, Issue 3, 2016, Pages 2754-2764

  Wang, Yongqiang ^a,b   Yu, Yuan ^c   Ye, Rui ^c   Zhang, Duo ^c   Li, Qiaoling ^c   An, Dan ^c   Fang, Lu ^d   Lin, Youcheng ^e   Hou, Yong ^c   Xu, Abai ^e   Fu, Yu ^f   Lu, Wei ^d   Chen, Xin ^a   Chen, Mingwei ^d   Zhang, Meng ^d   Jiang, Huiling ^g   Zhang, Chuanxia ^h   Dong, Pei ^a   Li, Chong ⁱ   Chen, Jun ^g   Yang, Guosheng ^f   Liu, Chunxiao ^e   Cai, Zhiming ^j   Zhou, Fangjian ^a   Wu, Song ^b,j   more..

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SHENZHEN UNIVERSITY   (China)

^c BGI SHENZHEN   (China)

^d ANHUI MEDICAL UNIVERSITY   (China)

^e SOUTHERN MEDICAL UNIVERSITY   (China)

^f GUANGDONG SECOND PROVINCIAL GENERAL HOSPITAL   (China)

^g SUN YAT SEN UNIVERSITY   (China)

^h SUN YAT SEN UNIVERSITY   (China)

ⁱ INSTITUTE OF BIOPHYSICS   (China)

^j THE FIRST AFFILIATED HOSPITAL OF SHENZHEN UNIVERSITY   (China)

more..

Author keywords

Biomarkers; Bladder cancer; Epigenetics; Methylation; QMSP

Indexed keywords

BIOLOGICAL MARKER; DNA; CADHERIN; POU4F2 PROTEIN, HUMAN; PROTOCADHERIN 17, HUMAN; TRANSCRIPTION FACTOR POU4F2; TUMOR MARKER;

ARTICLE; BLADDER CANCER; CONTROLLED STUDY; DNA METHYLATION; EOMES GENE; EPIGENETICS; GDF15 GENE; GENE; HAN CHINESE; HUMAN; KIDNEY CANCER; MAJOR CLINICAL STUDY; NID2 GENE; PCDH17 GENE; POU4F2 GENE; PROSTATE CANCER; TCF21 GENE; TRANSITIONAL CELL CARCINOMA; URINALYSIS; URINE SEDIMENT; UROLITHIASIS; ZNF154 GENE; CHINA; GENETICS; KIDNEY TUMOR; MALE; PATHOLOGY; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS; URINE; UROTHELIUM;

BIOMARKERS, TUMOR; CADHERINS; CHINA; DNA; DNA METHYLATION; HUMANS; KIDNEY NEOPLASMS; MALE; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTOR BRN-3B; URINARY BLADDER NEOPLASMS; URINARY CALCULI; UROTHELIUM;

EID: 84962310123     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6666     Document Type: Article

References (20)

1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014; 64:252-271.
2. Hao J, Chen WQ. Bladder cancer-2012 Chinese cancer registration report. Press of Military Medical Sciences. 2012; 97.
3. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, Roupret M. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011; 59:997-1008.
4. Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL, Cheung HY, Wong WS, Chan PS, Lai FM, To KF. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res. 2002; 8:464-470.
5. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res. 2004; 10:1887-1893.
6. Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W, Westra WH, Schoenberg M, Zahurak M, Goodman SN, Sidransky D. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst. 2006; 98:996-1004.
7. Costa VL, Henrique R, Danielsen SA, Duarte-Pereira S, Eknaes M, Skotheim RI, Rodrigues A, Magalhaes JS, Oliveira J, Lothe RA, Teixeira MR, Jeronimo C, Lind GE. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res. 2010; 16:5842-5851.
8. Renard I, Joniau S, van Cleynenbreugel B, Collette C, Naome C, Vlassenbroeck I, Nicolas H, de Leval J, Straub J, Van Criekinge W, Hamida W, Hellel M, Thomas A, et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur Urol. 2010; 58:96-104.
9. Reinert T, Borre M, Christiansen A, Hermann GG, Orntoft TF, Dyrskjot L. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation. PloS one. 2012; 7:e46297.
10. Costa VL, Henrique R, Danielsen SA, Eknaes M, Patricio P, Morais A, Oliveira J, Lothe RA, Teixeira MR, Lind GE, Jeronimo C. TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics. 2011; 6:1120-1130.
11. Chung W, Bondaruk J, Jelinek J, Lotan Y, Liang S, Czerniak B, Issa JP. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prev. 2011; 20:1483-1491.
12. Chen PC, Tsai MH, Yip SK, Jou YC, Ng CF, Chen Y, Wang X, Huang W, Tung CL, Chen GC, Huang MM, Tong JH, Song EJ, et al. Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine. BMC Med Genomics. 2011; 4:45.
13. Su SF, de Castro Abreu AL, Chihara Y, Tsai Y, Andreu-Vieyra C, Daneshmand S, Skinner EC, Jones PA, Siegmund KD, Liang G. A panel of three markers hyper-and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res. 2014; 20:1978-1989.
14. Zhao Y, Guo S, Sun J, Huang Z, Zhu T, Zhang H, Gu J, He Y, Wang W, Ma K, Wang J, Yu J. Methylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a Chinese population. PloS one. 2012; 7:e35175.
15. Chihara Y, Kanai Y, Fujimoto H, Sugano K, Kawashima K, Liang G, Jones PA, Fujimoto K, Kuniyasu H, Hirao Y. Diagnostic markers of urothelial cancer based on DNA methylation analysis. BMC cancer. 2013; 13:275.
16. Beukers W, Kandimalla R, van Houwelingen D, Kovacic H, Chin JF, Lingsma HF, Dyrskjot L, ZwarthoffEC. The use of molecular analyses in voided urine for the assessment of patients with hematuria. PloS one. 2013; 8:e77657.
17. Lee C, Kim J, Shin SG, Hwang S. Absolute and relative QPCR quantification of plasmid copy number in Escherichia coli. J Biotechnol. 2006; 123:73-280.
18. Lin HH, Ke HL, Huang SP, Wu WJ, Chen YK, Chang LL. Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine. Urol Oncol. 2010; 28:597-602.
19. Reinert T, Modin C, Castano FM, Lamy P, Wojdacz TK, Hansen LL, Wiuf C, Borre M, Dyrskjot L, Orntoft TF. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res. 2011; 17:5582-5592.
20. Whelan JA, Russell NB, Whelan MA. A method for the absolute quantification of cDNA using real-time PCR. J Immunol Methods. 2003; 278:261-269.